Zynlonta

Zynlonta
Pharma

ADC touts early Zynlonta results in marginal zone lymphoma

ADC Therapeutics provided several updates Monday, including that it's raising $105 million through a sale of common shares and pre-funded warrants.
Eric Sagonowsky May 6, 2024 4:19pm
stop shut down close end button

ADC Therapeutics scraps Zynlonta study after FDA partial hold

Jul 21, 2023 11:13am
pause hold stop delay

ADC pauses Zynlonta study after 7 patient deaths

Jul 11, 2023 12:23pm
Zynlonta

ADC Therapeutics taps Sobi to market Zynlonta outside of US

Jul 8, 2022 10:55am
Headshot of new ADC Therapeutics Chief Business Strategy Officer

David Gilman joins Ameet Mallik on ADC Therapeutics' exec board

Jun 14, 2022 3:57pm
Image of ADC Therapeutics new CEO Ameet Mallik

ADC Therapeutics lures former Novartis exec as new CEO

May 9, 2022 10:36am